Patients treated with Eli Lilly Alzheimer’s disease drug donanemab showed a 35% slowing in decline compared to those given a placebo. Based on the Phase 3 results, Lilly said it would seek FDA approval for the drug by the end of June.
Though the tragic death of noted Alzheimer's researcher Dr. Mark Smith has silenced the voice of one of the leading critics of the so-called amyloid theory, Smith's Case Western Reserve University colleagues expect to carry on his work.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
The University of Minnesota said Wednesday that scientists have established a firm relationship between a protein known as tau and Alzheimer’s disease, the most common form of elderly dementia in the United States. In a study published in the journal Neuron, researchers say that an early buildup of tau in the dendritic spines, a region […]